Condition: Low-grade Glioma · Advanced Solid Tumor · Sponsor: Day One Biopharmaceuticals, Inc.
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified through molecular assays as routinely performed at Clinical Laboratory Improvement Amendments (CLIA) of 1988 or other similarly certified laboratories prior to enrollment into any of the arms. The study will consist of a screening period, a treatment period, a long-term extension phase, end of treatment (EOT) visit(s), a safety follow-up visit, and long-term follow-up assessments.
This description comes directly from the study's public registry record.
Day One Biopharmaceuticals, Inc. · 650-484-0899 · firefly-1@dayonebio.com
Always discuss trial participation with your own doctor first.
| UCSF Benioff Children's Hospital | San Francisco, California, United States | Recruiting |
| Children's National Medical Center | Washington D.C., District of Columbia, United States | Recruiting |
| Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Recruiting |
| Johns Hopkins Hospital | Baltimore, Maryland, United States | Terminated |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| CS Mott Children's Hospital | Ann Arbor, Michigan, United States | Recruiting |
| St. Louis Children's Hospital | St Louis, Missouri, United States | Recruiting |
| NYU Langone Health | New York, New York, United States | Recruiting |
| Duke Cancer Center | Durham, North Carolina, United States | Recruiting |
| Doernbecher Children's Hospital Oregon & Health Science University | Portland, Oregon, United States | Terminated |
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| Texas Children's Hospital | Houston, Texas, United States | Recruiting |
+ 23 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04775485